Across 25 endpoint-bearing reviewed Phase III pancreatic cancer trials, overall survival was the dominant hard efficacy endpoint. PFS was rarely used without OS; when PFS appeared, it was usually paired with OS either as a co-primary/composite signal or as a secondary endpoint supporting the survival architecture.
OS appeared as a primary endpoint in 44.0% of reviewed trials. PFS appeared as a primary endpoint in 16.0%, but half of that use was part of an OS/PFS co-primary or composite survival architecture rather than standalone PFS primacy.
The endpoint pattern is OS-led. PFS is present, but it more often functions as a paired or supporting endpoint than as the sole primary efficacy anchor.
PFS did not appear as an isolated endpoint strategy in the reviewed dataset. Every trial with PFS also included OS somewhere in the endpoint architecture, while OS appeared without PFS in 24.0% of trials.
PFS appears operationally important but not independently dominant. The observed pattern treats PFS as a progression-control readout that usually needs the interpretive support of OS in Phase III pancreatic cancer designs.
Advanced, metastatic, or unresectable pancreatic cancer trials were much more likely to use OS or PFS as the primary efficacy anchor. Resected, resectable, or post-curative-intent trials more often shifted toward DFS or EFS, while still retaining OS as a secondary or supporting endpoint.
The setting signal is clear: metastatic or unresectable trials concentrate OS/PFS primary endpoints, while curative-intent or resected settings more often move the primary endpoint upstream to DFS or EFS.
OS was present somewhere in 76.0% of reviewed trials, while PFS was present in 52.0%. DFS, EFS, or related recurrence endpoints appeared in 24.0%, mainly in post-surgical or potentially curative settings.
Pancreatic cancer Phase III endpoint design is layered rather than binary. OS is the dominant interpretive endpoint, PFS is commonly paired with it, and DFS/EFS captures earlier disease-control logic in curative-intent settings.
The observed CTIS dataset does not show PFS replacing OS as the central Phase III endpoint in pancreatic cancer. Instead, OS remains the main anchor, especially in advanced or metastatic disease, while PFS is used as a progression-control layer and DFS/EFS becomes more prominent when the trial setting moves closer to surgery, recurrence prevention, or curative-intent treatment.
The data suggest a pragmatic endpoint hierarchy: OS for definitive survival impact, PFS for progression-control context, and DFS/EFS for earlier-stage recurrence-risk settings. The clearest pancreatic cancer signal is not OS versus PFS as substitutes, but OS as the anchor around which PFS and recurrence endpoints are layered.